HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

L'Oreal

This article was originally published in The Rose Sheet

Executive Summary

Cosmetics sales grew 11.9% to $10.5 bil. in 1999 and profit before taxes and employee sharing rose 13.2% to $1.12 bil. Dermatology sales jumped 31.6% to $199 mil. Consolidated worldwide sales increased 12.1% to $10.77 bil. in 1999, and net profits before capital gains/losses jumped 15.3% to $698 mil. Sales growth is based on pro forma figures, excluding Synthelabo, which merged with Sanofi in 1999. L'Oreal sales achieved a 4% positive structural impact due to the consolidation of cosmetics and dermatology subsidiaries in the U.S

You may also be interested in...



L'Oreal

North American cosmetic sector profits reached an18.3% increase in 1999, the firm reports. Consolidated operating profit grew 12.1% to approximately $10.4 bil. (70.52 bil. FFr) and net profit climbed 15.1% to $798.6 mil. (5.43 bil. FFr). L'Oreal launched two Web sites for Lancome and Le Club des Createurs de Beaute during the year. A cosmetics sales increase of 11.9% to $10.5 bil. for 1999 previously was reported (1"The Rose Sheet" Feb. 28, In Brief). First quarter consolidated sales rose 15.5% to roughly $2.9 bil. (19.8 bil. FFr) in 2000 and cosmetics sales increased 15.3%

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
UsernamePublicRestriction

Register

RS007703

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel